PFIZER INC.
πΊπΈUnited States
- Country
- πΊπΈUnited States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
A Study to Determine if Antibiotics Prevent Infection in the Pancreas of Patients Where Part of the Pancreas Has Died
Phase 4
Completed
- Conditions
- First Posted Date
- 2003-05-28
- Last Posted Date
- 2017-09-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 240
- Registration Number
- NCT00061438
- Locations
- π¨π¦
Research Site, Montreal, Quebec, Canada
Study Evaluating Sumanirole for the Treatment of the Signs and Symptoms of Early Parkinson's Disease
Phase 3
Completed
- Conditions
- First Posted Date
- 2003-04-15
- Last Posted Date
- 2006-06-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 854
- Registration Number
- NCT00058838
- Locations
- πͺπΈ
Pfizer Investigational Site, Zaragoza, Spain
Treatment With SU11248 in Patients With Neuroendocrine Tumors
- First Posted Date
- 2003-03-24
- Last Posted Date
- 2008-07-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 107
- Registration Number
- NCT00056693
- Locations
- πΊπΈ
Pfizer Investigational Site, Philadelphia, Pennsylvania, United States
The Safety and Efficacy of Anidulafungin Versus Comparator in Patients With Candidemia and Invasive Candidiasis
Phase 3
Completed
- Conditions
- First Posted Date
- 2003-03-12
- Last Posted Date
- 2008-10-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 256
- Registration Number
- NCT00056368
- Locations
- πΊπΈ
Versicor, Inc., King of Prussia, Pennsylvania, United States
Safety, Tolerance and Pharmacokinetics of Anidulafungin in Immunocompromised Children Ages 2-17
Phase 1
Completed
- Conditions
- First Posted Date
- 2003-03-12
- Last Posted Date
- 2008-10-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 25
- Registration Number
- NCT00056381
- Locations
- πΊπΈ
Versicor, King of Prussia, Pennsylvania, United States
Study of the Safety and Efficacy of SU-011,248 in Adult Patients With Advanced Kidney Cancer
Phase 2
Completed
- Conditions
- First Posted Date
- 2003-02-13
- Last Posted Date
- 2007-05-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 63
- Registration Number
- NCT00054886
- Locations
- πΊπΈ
Pfizer Investigational Site, Madison, Wisconsin, United States
Four-Drug Combination Treatment in Hiv-Infected Subjects Failing Therapy With Antiretroviral Regimens
Phase 2
Completed
- Conditions
- First Posted Date
- 2003-01-23
- Last Posted Date
- 2007-10-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 300
- Registration Number
- NCT00052117
Capravirine (AG1549) in Combination With Viracept and Two NRTIs in HIV Infected Patients Who Failed an Initial NNRTI Containing Regimen
Phase 2
Completed
- Conditions
- First Posted Date
- 2003-01-20
- Last Posted Date
- 2011-05-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 179
- Registration Number
- NCT00051844
- Locations
- πͺπΈ
Pfizer Investigational Site, Cordoba, Spain
A Phase II Study of CI-1033 in Treating Patients With Metastatic (Stage IV) Breast Cancer
Phase 2
Completed
- Conditions
- First Posted Date
- 2003-01-03
- Last Posted Date
- 2007-05-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 168
- Registration Number
- NCT00051051
- Locations
- π¬π§
Pfizer Investigational Site, London, United Kingdom
A Phase 2, Randomized, Open-Label Study Of Single Agent CI-1033 In Patients With Advanced Non-Small Cell Lung Cancer
Phase 2
Completed
- Conditions
- First Posted Date
- 2002-12-24
- Last Posted Date
- 2006-11-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 163
- Registration Number
- NCT00050830
- Locations
- π¬π§
Pfizer Investigational Site, London, United Kingdom
Β© Copyright 2024. All Rights Reserved by MedPath